Method of directing biosynthesis of specific polyketides
    14.
    发明授权
    Method of directing biosynthesis of specific polyketides 失效
    指导特定聚酮化合物的生物合成方法

    公开(公告)号:US6004787A

    公开(公告)日:1999-12-21

    申请号:US439009

    申请日:1995-05-11

    CPC分类号: C07H17/08 C12N15/52 C12P19/62

    摘要: A method to produce novel polyketide structures by designing and introducing specified changes in the DNA governing the synthesis of the polyketide is disclosed. The biosynthesis of specific polyketide analogs is accomplished by genetic manipulation of a polyketide-producing microorganism by isolating a polyketide biosynthetic gene-containing DNA sequence, identifying enzymatic activities associated within the DNA sequence, introducing one or more specified changes into the DNA sequence which codes for one of the enzymatic activities which results in an altered DNA sequence, introducing the altered DNA sequence into the polyketide-producing microorganism to replace the original sequence, growing a culture of the altered microorganism under conditions suitable for the formation of the specific polyketide analog, and isolating the specific polyketide analog from the culture. The method is most useful when the segment of the chromosome modified is involved in an enzymatic activity associated with polyketide biosynthesis, particularly for manipulating polyketide synthase genes from Saccarharopolyspora or Streptomyces.

    摘要翻译: 公开了一种通过设计和引入控制聚酮化合物合成的DNA的特定变化产生新型聚酮化合物结构的方法。 特定聚酮化合物类似物的生物合成是通过分离含聚酮化合物生物合成基因的DNA序列,鉴定DNA序列内相关的酶活性,将一个或多个特定变化导入DNA序列的遗传操作来实现的, 导致改变的DNA序列的酶活性之一,将改变的DNA序列引入聚酮化合物生产微生物中以替代原始序列,在适于形成特定聚酮化合物类似物的条件下培养改变的微生物的培养物;以及 从培养物中分离特定的聚酮化合物类似物。 当染色体修饰的片段参与与聚酮化合物生物合成相关的酶活性,特别是用于操作来自蛔虫多孢菌或链霉菌的聚酮化合物合酶基因时,该方法是最有用的。

    Method of producing 2-epi-fortimicin A
    17.
    发明授权
    Method of producing 2-epi-fortimicin A 失效
    制备2-epi-fortimicin的方法A

    公开(公告)号:US4418193A

    公开(公告)日:1983-11-29

    申请号:US366800

    申请日:1982-04-09

    IPC分类号: C07H15/224 C07H15/22

    CPC分类号: C07H15/224 Y02P20/55

    摘要: An improved method of producing 2-epi-fortimicin A directly from fortimicin A by protecting the amine functions of fortimicin A, converting the N-protected fortimicin A to an intermediate of the formula: ##STR1## wherein L is a leaving group and Z is an amine-protecting group, reacting the intermediate (I) with a loweralkyl metal halide in N,N-dimethylformamide to form N-protected-2-epi-fortimicin A, and then hydrogenating the N-protected-2-epi-fortimicin A to obtain 2-epi-fortimicin A.

    摘要翻译: 通过保护苦丁霉素A的胺官能团,将N-保护的fortimicin A转化为下式的中间体,其中L是离去基团,其中L是离去基团 并且Z是胺保护基团,使中间体(I)与N,N-二甲基甲酰胺中的低级烷基金属卤化物反应,形成N-保护的2-表 - 敌霉素A,然后将N-保护的2-表面 - 有益霉素A获得2-epi-fortimicin A.

    Seldomycin factor 5 derivatives
    18.
    发明授权
    Seldomycin factor 5 derivatives 失效
    西妥昔单抗5型衍生物

    公开(公告)号:US4189569A

    公开(公告)日:1980-02-19

    申请号:US922134

    申请日:1978-07-05

    CPC分类号: C07H15/234 C12P19/485

    摘要: Described are novel derivatives of seldomycin factor 5 (XK-88-5) and particularly 3'-Epi-seldomycin factor 5, which exhibit improved activity against gram-positive and gram-negative bacteria resistant to aminoglycoside antibiotics, and a method of preparing them.

    摘要翻译: 描述了对青霉素因子5(XK-88-5)特别是3-Epi-seldomycin因子5的新型衍生物,其对抗氨基糖苷类抗生素的革兰氏阳性和革兰氏阴性菌具有改善的活性,以及​​制备它们的方法 。

    Substituted aurone derivatives
    19.
    发明授权
    Substituted aurone derivatives 失效
    取代的鸢尾衍生物

    公开(公告)号:US06307070B1

    公开(公告)日:2001-10-23

    申请号:US09122257

    申请日:1998-07-24

    IPC分类号: C07D30783

    摘要: A method for treating a fungal infection is disclosed. The method includes administering to a patient a pharmaceutical composition containing a compound of formula (IA): where each R is independently H, OH, Br, Cl, I, amino, thiol, nitro, C1-4 alkoxy, C1-4 alkenyloxy, C2-6 alkoxyalkyleneoxy, C1-4 alkylthio, C3-18 alkyl, or C3-18 alkenyl; or two adjacent R's, taken together, are a C2-18 bivalent moiety containing at least one oxgen atom, substituted or disubstituted with A or B or both, A being H, OH, Br, Cl, I, amino, or thiol, and B being H, C1-10 alkyl, C2-18 alkenyl, or C6-18 aryl; provided at least two Rs are not H; X is C4-10 alkyl, C4-20 alkenyl, or a C4-20 single, C6-20 bridged, or C6-20 fused ring moiety containing cycloalkyl, cycloalkenyl, aryl, heterocycle, or heteroaryl, where X is substituted with H, OH, Cl, Br, I, amino, cyano, nitro, alkyl, alkoxy, alkenyl, or alkenyloxy; provided that if X is a heteroaryl or heterocyclic moiety where two Rs are each OH and meta to each other, then the remaining R is H and ortho to each of the two hydroxyls, and Y and Z are each O and a ring atom of X is linked directly to the sp2 carbon atom adjacent to X, then substituted with H, OH, Cl, Br, I, amino, cyano, alkyl, alkoxy, alkenyl, or alkenyloxy; and each of Y and Z is independently selected from O, S, and NH; or a pharmaceutically acceptable salt or ester thereof.

    摘要翻译: 公开了一种治疗真菌感染的方法。 该方法包括向患者施用含有式(IA)化合物的药物组合物:其中每个R独立地为H,OH,Br,Cl,I,氨基,硫醇,硝基,C 1-4烷氧基,C 1-4链烯氧基, C 2-6烷氧基亚烷基氧基,C 1-4烷硫基,C 3-8烷基或C 3-8烯基; 或两个相邻的R一起是含有至少一个被A或B或两者取代或二取代的氧原子的C2-18二价部分,A是H,OH,Br,Cl,I,氨基或硫醇,以及 B是H,C 1-10烷基,C 2-8烯基或C 6-18芳基; 提供至少两个R不是H; X是C 4-10烷基,C 4-20链烯基,或含有环烷基,环烯基,芳基,杂环或碳原子的C 4-20单-C6-20桥环或C6-20稠环部分 杂芳基,其中X被H,OH,Cl,Br,I,氨基,氰基,硝基,烷基,烷氧基,烯基或烯氧基取代; 条件是如果X是杂芳基或杂环部分,其中两个R 5各自为OH并且彼此相互间隔,则剩余的R是H和两个羟基中的每一个的邻位,Y和Z各自为O,X为环原子 直接与X相邻的sp2碳原子连接,然后用H,OH,Cl,Br,I,氨基,氰基,烷基,烷氧基,烯基或烯氧基取代; Y和Z各自独立地选自O,S和NH; 或其药学上可接受的盐或酯。